Editas Medicine

(NASDAQ: EDIT)
Healthcare  |  Biotechnology
30.92 0.53 1.74%
Stock Price | Dec. 6, 2019, 4 p.m.
0 Followers
Bid: 0.0
Ask: 0.0
Prev. Close: 30.39
52 Week Low: 17.8
52 Week High: 31.78
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company operates its business in a single segment of Developing and commercializing genome editing technology.

Read more Read less

Recently Viewed Tickers

Free Stock Watchlist 09/07/2016

3 years ago